Development of a novel anti-FimH vaccine using a mast cell activator as the adjuvant. (94.1)
| Autor: | Christopher Shelburne, Guojie Li, Herman Staats, Soman Abraham |
|---|---|
| Rok vydání: | 2010 |
| Předmět: | |
| Zdroj: | The Journal of Immunology. 184:94.1-94.1 |
| ISSN: | 1550-6606 0022-1767 |
| DOI: | 10.4049/jimmunol.184.supp.94.1 |
| Popis: | Urinary tract infections (UTIs) are one of the most common bacterial infections of man. Because of their high rate of recurrence and the increase in resistance of bacteria to antibiotics, there is great interest in developing a prophylactic vaccine to limit UTIs. Unfortunately, efforts to develop such a vaccine have failed in humans, quite possibly due to the use of alum as the vaccine adjuvant which does not induce protective immune responses along the urinary tract. Here, we demonstrate that a novel anti-UTI vaccine formulation consisted of the UTI vaccine antigen FimH and a mucosal mast cell activating adjuvant compound, mastoparan-7 is able to evoke protective immune responses against UTI. This vaccine formulation induced high titer anti-FimH IgA and IgG in both the urine and serum of immunized mice that were protective against subsequent challenge of the bladder site with uropathogenic E. coli. These anti-FimH responses were comparable to those elicited by FimH vaccine formulations containing cholera toxin as the adjuvant, and superior to those elicited by formulations containing the adjuvants CpGs or alum. These studies suggest that formulation of an anti-UTI vaccine with a MC activator and the FimH antigen might result in a successful anti-UTI vaccine in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|